他莫昔芬及其代謝產(chǎn)物血藥濃度與ER陽性乳腺癌患者子宮內(nèi)膜增生的相關(guān)性研究
發(fā)布時(shí)間：2018-10-14 08:42
【摘要】：目的:考察他莫昔芬(TAM)及其代謝產(chǎn)物血藥濃度與雌激素受體(ER)陽性乳腺癌患者子宮內(nèi)膜增生的相關(guān)性。方法:選取2015年3月-2016年4月我院ER陽性乳腺癌患者69例,均接受TAM持續(xù)治療半年以上(每日2次,每次1片)。根據(jù)治療后其子宮內(nèi)膜厚度分為異常增生組(40例)和正常組(29例),采用高效液相色譜-熒光法測(cè)定其體內(nèi)TAM及代謝產(chǎn)物[4-羥基他莫昔芬(OHT)、N-去甲基他莫昔芬(DMT)和Endoxifen]的穩(wěn)態(tài)血藥濃度,采用Pearson檢驗(yàn)和多元回歸分析考察血藥濃度等因素與子宮內(nèi)膜厚度的相關(guān)性。結(jié)果:異常增生組患者的用藥時(shí)間、Endoxifen穩(wěn)態(tài)血藥濃度均顯著長于或高于正常組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05);而兩組患者年齡,體質(zhì)量指數(shù),并發(fā)癥以及TAM、OHT、DMT穩(wěn)態(tài)血藥濃度比較,差異均無統(tǒng)計(jì)學(xué)意義(P0.05)�；颊咦訉m內(nèi)膜厚度與Endoxifen穩(wěn)態(tài)血藥濃度和用藥時(shí)間呈正相關(guān)性(r分別為0.447、0.460,P0.05);以子宮內(nèi)膜厚度(y)為因變量,用藥時(shí)間(x_1)和Endoxifen穩(wěn)態(tài)血藥濃度(x_2)為自變量,進(jìn)行多元回歸分析,得回歸方程為y=2.436+0.123x_1+0.082x_2(F=12.610,r=0.526,P0.05)。結(jié)論:Endoxifen穩(wěn)態(tài)血藥濃度和患者用藥時(shí)間可能與子宮內(nèi)膜增生有關(guān),可為臨床預(yù)測(cè)TAM致ER陽性乳腺癌患者子宮內(nèi)膜異常增生提供參考。
[Abstract]:Aim: to investigate the relationship between serum concentration of tamoxifen (TAM) and its metabolites and endometrial hyperplasia in patients with estrogen receptor (ER) positive breast cancer. Methods: 69 patients with ER positive breast cancer in our hospital from March 2015 to April 2016 were treated with TAM for more than half a year (1 tablet twice a day). According to the thickness of endometrium after treatment, the endometrium was divided into two groups: abnormal hyperplasia group (40 cases) and normal group (29 cases). TAM and its metabolites [4-hydroxytamoxifene (OHT), N-demethamoxifene (DMT) and Endoxifen] were determined by high performance liquid chromatography-fluorescence method. Steady-state blood drug concentration, The correlation between blood drug concentration and endometrial thickness was investigated by Pearson test and multiple regression analysis. Results: the drug use time and Endoxifen steady-state concentration in patients with abnormal hyperplasia were significantly longer than or higher than those in normal controls (P0.05), while the age, body mass index, complications and steady-state serum concentration of TAM,OHT,DMT were compared between the two groups. The difference was not statistically significant (P0.05). The endometrial thickness was positively correlated with the steady-state serum concentration and duration of Endoxifen (r = 0.4470.460,0.05), the endometrial thickness of (y) was taken as dependent variable, the time of administration (xStu1) and the steady-state blood drug concentration of Endoxifen (x2) were used as independent variables, and the multivariate regression analysis was carried out. The regression equation was 2.436 0.123x_1 0.082x_2 (F _ (12. 610) ~ 0. 526 ~ 0. 05). Conclusion: the steady-state blood concentration of Endoxifen and the duration of treatment may be related to endometrial hyperplasia, which may provide a reference for clinical prediction of abnormal hyperplasia of endometrium in patients with ER positive breast cancer induced by TAM.
【作者單位】： 南京醫(yī)科大學(xué)附屬南京醫(yī)院/南京市第一醫(yī)院藥學(xué)部;
【基金】：江蘇省藥學(xué)會(huì)奧賽康臨床藥學(xué)立項(xiàng)課題(No.201209)
【分類號(hào)】：R969
本文編號(hào)：2269952
[Abstract]:Aim: to investigate the relationship between serum concentration of tamoxifen (TAM) and its metabolites and endometrial hyperplasia in patients with estrogen receptor (ER) positive breast cancer. Methods: 69 patients with ER positive breast cancer in our hospital from March 2015 to April 2016 were treated with TAM for more than half a year (1 tablet twice a day). According to the thickness of endometrium after treatment, the endometrium was divided into two groups: abnormal hyperplasia group (40 cases) and normal group (29 cases). TAM and its metabolites [4-hydroxytamoxifene (OHT), N-demethamoxifene (DMT) and Endoxifen] were determined by high performance liquid chromatography-fluorescence method. Steady-state blood drug concentration, The correlation between blood drug concentration and endometrial thickness was investigated by Pearson test and multiple regression analysis. Results: the drug use time and Endoxifen steady-state concentration in patients with abnormal hyperplasia were significantly longer than or higher than those in normal controls (P0.05), while the age, body mass index, complications and steady-state serum concentration of TAM,OHT,DMT were compared between the two groups. The difference was not statistically significant (P0.05). The endometrial thickness was positively correlated with the steady-state serum concentration and duration of Endoxifen (r = 0.4470.460,0.05), the endometrial thickness of (y) was taken as dependent variable, the time of administration (xStu1) and the steady-state blood drug concentration of Endoxifen (x2) were used as independent variables, and the multivariate regression analysis was carried out. The regression equation was 2.436 0.123x_1 0.082x_2 (F _ (12. 610) ~ 0. 526 ~ 0. 05). Conclusion: the steady-state blood concentration of Endoxifen and the duration of treatment may be related to endometrial hyperplasia, which may provide a reference for clinical prediction of abnormal hyperplasia of endometrium in patients with ER positive breast cancer induced by TAM.
【作者單位】： 南京醫(yī)科大學(xué)附屬南京醫(yī)院/南京市第一醫(yī)院藥學(xué)部;
【基金】：江蘇省藥學(xué)會(huì)奧賽康臨床藥學(xué)立項(xiàng)課題(No.201209)
【分類號(hào)】：R969
【相似文獻(xiàn)】
相關(guān)期刊論文 前1條
1 何芳;宋淑芬;何慧;;個(gè)案管理模式對(duì)ER陽性乳腺癌生命質(zhì)量的影響研究[J];齊齊哈爾醫(yī)學(xué)院學(xué)報(bào);2014年09期
相關(guān)碩士學(xué)位論文 前1條
1 陳慧;ER陽性乳腺癌輔助內(nèi)分泌治療耐藥的相關(guān)因素及血清miRNAs的研究[D];南京大學(xué);2015年
，本文編號(hào)：2269952
本文鏈接：http://sikaile.net/yixuelunwen/yiyaoxuelunwen/2269952.html
最近更新
教材專著
